Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II—The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Context.—: The world of oncology has changed dramatically in the past few years with the introduction of checkpoint inhibitors and immunotherapy. The promising findings of a small, phase 2 clinical trial that led to the US Food and Drug Administration breakthrough designation and approval of the anti–programmed death receptor-1 (PD-1) drug pembrolizumab (Keytruda, Merck, Kenilworth, New Jersey) to treat metastatic/refractory microsatellite instability–high colorectal cancer (CRC) has significantly boosted interest in immunomodulatory therapies in microsatellite instability–high CRC. Objectives.—: To review the immune response to cancer and the role of immune checkpoints, focusing on the technical and interpretation challenges of PD-1/programmed death ligand-1 (PD-L1) testing by pathologists and the clinical implications of the test and the therapeutic potential of treating CRC with checkpoint inhibitors. Data Sources.—: A PubMed review was performed of articles pertaining to CRC, microsatellite instability and mismatch repair systems, molecular classification, immune response, PD-1/PD-L1, and immunotherapy. Conclusions.—: Exciting success with anti–PD-1/PD-L1 and anticytotoxic T-lymphocyte–associated protein 4 (CTLA4) checkpoint inhibitors has already been reported in melanoma and in lung and renal carcinomas. Recently, microsatellite instability–high CRCs, expressing PD-L1 by immunohistochemistry, regardless of the level of that PD-L1 expression, appeared to respond to checkpoint blockades with anti–PD-1 or anti–PD-L1 agents, whereas microsatellite-stable tumors were much less responsive. With microsatellite instability routinely tested by most centers, studies that include larger cohorts are required to study the predictive role of PD-1/PD-L1 expression in microsatellite instability–high CRC, to assess which immunohistochemistry antibodies to use, to refine the scoring criteria, and to critically analyze the interpretation pitfalls.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal.(8) Targeting CTLA4 by ipilimumab blocks its binding to CD80/CD86 and turns off its inhibitory mechanism, thus allowing T cells to destroy the tumor cells.”
BackgroundLlosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
Lee, L. H., Cavalcanti, M. S., Segal, N. H., Hechtman, J. F., Weiser, M. R., Smith, J. J., Garcia-Aguilar, J., Sadot, E., Ntiamoah, P., Markowitz, A. J., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.139 · Cited by 186 · cited 1×
“However, a few studies showed that PD-L1 testing by IHC is feasible in CRC, and their high-level expression correlated with microsatellite status and histologic features usually associated with MSI-H and predicted clinical response to anti–PD-1/PD-L1 inhibitors.(1,23) Larger studies are required to study the predictiv…”
Result
Cited by
Lenz, H.-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01015 · Cited by 728
Morse, M. A., Overman, M. J., Hartman, L., Khoukaz, T., Brutcher, E., Lenz, H.-J., Atasoy, A., Shangguan, T., Zhao, H., & El-Rayes, B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0129 · Cited by 112
Borelli, B., Antoniotti, C., Carullo, M., Germani, M. M., Conca, V., & Masi, G. (2022) · Cancers · doi:10.3390/cancers14204974 · Cited by 62
“At the multivariate analysis, both PD-1 and PD-L1 expression confirmed their independent association with recurrence-free survival only in the dMMR/MSI-H group, while they did not in the pMMR/MSS group [64,65].”
Method
Metadata
- Authors
- Marginean, E. C., & Melosky, B.
- Venue
- Archives of Pathology & Laboratory Medicine
- Published
- 2017-11-09
- Volume
- 142
- Issue
- 1
- Pages
- 26-34
- ISSN
- 0003-9985 (ISSN-L)
- 1543-2165
- OpenAlex
- W2767221986
- Cited by
- 39
- References
- 3
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II—The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. https://app.cochat.ai/papers/10.5858/arpa.2017-0041-ra
- The paper
- Marginean, E. C., & Melosky, B. (2018). Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II—The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. Archives of Pathology & Laboratory Medicine. https://doi.org/10.5858/arpa.2017-0041-ra
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.